Neuroblastoma: an ongoing cold front for cancer immunotherapy.
Immunotherapy
Neuroblastoma
Tumor Microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
accepted:
28
10
2023
medline:
24
11
2023
pubmed:
23
11
2023
entrez:
22
11
2023
Statut:
epublish
Résumé
Neuroblastoma is the most frequent extracranial childhood tumour but effective treatment with current immunotherapies is challenging due to its immunosuppressive microenvironment. Efforts to date have focused on using immunotherapy to increase tumour immunogenicity and enhance anticancer immune responses, including anti-GD2 antibodies; immune checkpoint inhibitors; drugs which enhance macrophage and natural killer T (NKT) cell function; modulation of the cyclic GMP-AMP synthase-stimulator of interferon genes pathway; and engineering neuroblastoma-targeting chimeric-antigen receptor-T cells. Some of these strategies have strong preclinical foundation and are being tested clinically, although none have demonstrated notable success in treating paediatric neuroblastoma to date. Recently, approaches to overcome heterogeneity of neuroblastoma tumours and treatment resistance are being explored. These include rational combination strategies with the aim of achieving synergy, such as dual targeting of GD2 and tumour-associated macrophages or natural killer cells; GD2 and the B7-H3 immune checkpoint; GD2 and enhancer of zeste-2 methyltransferase inhibitors. Such combination strategies provide opportunities to overcome primary resistance to and maximize the benefits of immunotherapy in neuroblastoma.
Identifiants
pubmed: 37993280
pii: jitc-2023-007798
doi: 10.1136/jitc-2023-007798
pmc: PMC10668262
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Nat Commun. 2022 May 31;13(1):3022
pubmed: 35641483
Mol Cancer. 2019 Nov 4;18(1):152
pubmed: 31679519
Oncoimmunology. 2021 Jan 4;10(1):1838140
pubmed: 33489468
JCO Clin Cancer Inform. 2018 Dec;2:1-15
pubmed: 30652588
Cancers (Basel). 2021 May 30;13(11):
pubmed: 34070756
Lancet Oncol. 2018 Dec;19(12):1617-1629
pubmed: 30442501
Cancer Immunol Immunother. 2022 Jan;71(1):71-83
pubmed: 34023958
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
J Clin Invest. 2012 Sep;122(9):3260-70
pubmed: 22863621
Nat Med. 2020 Nov;26(11):1686-1690
pubmed: 33046868
Oncoimmunology. 2017 Apr 28;6(6):e1320626
pubmed: 28680756
J Immunother Cancer. 2019 Dec 6;7(1):344
pubmed: 31810498
JAMA Oncol. 2018 Dec 1;4(12):1729-1735
pubmed: 30326045
Oncoimmunology. 2017 Jul 31;6(11):e1358331
pubmed: 29147617
Immunity. 2016 May 17;44(5):955-72
pubmed: 27192563
Cancer Res. 2014 Sep 15;74(18):5057-69
pubmed: 25082815
J Clin Oncol. 2009 Jan 10;27(2):298-303
pubmed: 19047290
Front Immunol. 2021 Nov 09;12:781032
pubmed: 34858438
Neuron. 2022 Sep 21;110(18):2916-2928
pubmed: 35985323
Cancer Res. 2021 Aug 1;81(15):3945-3952
pubmed: 33903123
Oncoimmunology. 2017 Jul 5;6(10):e1343775
pubmed: 29123953
MAbs. 2016;8(3):604-16
pubmed: 26785755
Biochim Biophys Acta Rev Cancer. 2022 Nov;1877(6):188805
pubmed: 36162542
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32169869
Cancer Sci. 2018 Jan;109(1):141-153
pubmed: 29151270
Oncoimmunology. 2018 May 10;7(8):e1461305
pubmed: 30221057
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Lancet Oncol. 2020 Apr;21(4):474-476
pubmed: 32192574
Cancers (Basel). 2021 Aug 24;13(17):
pubmed: 34503071
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Front Immunol. 2015 Jul 27;6:368
pubmed: 26284063
Drugs. 2015 May;75(8):923-7
pubmed: 25940913
Immunity. 2008 Sep 19;29(3):391-403
pubmed: 18703361
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33504575
Clin Cancer Res. 1996 Dec;2(12):1951-9
pubmed: 9816154
Eur J Cancer. 2021 Jun;150:53-62
pubmed: 33892407
Lancet Oncol. 2020 Apr;21(4):541-550
pubmed: 32192573
Nat Rev Drug Discov. 2020 Mar;19(3):200-218
pubmed: 31907401
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32221013
J Immunother Cancer. 2019 Apr 29;7(1):115
pubmed: 31036082
J Clin Oncol. 2015 Sep 20;33(27):3008-17
pubmed: 26304901
Cancers (Basel). 2021 Dec 14;13(24):
pubmed: 34944886
N Engl J Med. 1985 Oct 31;313(18):1111-6
pubmed: 4047115
Front Immunol. 2020 May 08;11:873
pubmed: 32457760
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
J Clin Oncol. 2014 May 10;32(14):1445-52
pubmed: 24711551
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
J Immunother Cancer. 2021 Aug;9(8):
pubmed: 34341132
PLoS One. 2016 Oct 7;11(10):e0164401
pubmed: 27716850
Nat Med. 2022 Feb;28(2):333-344
pubmed: 35027753
J Pathol. 2016 Oct;240(2):211-23
pubmed: 27425378
J Clin Oncol. 2022 Feb 1;40(4):335-344
pubmed: 34871104
Front Oncol. 2020 Jul 07;10:1000
pubmed: 32733795
Cancer. 2013 Aug 1;119(15):2789-95
pubmed: 23633099
Cancer Res. 2017 Jul 1;77(13):3619-3631
pubmed: 28512240
Clin Cancer Res. 2021 Apr 15;27(8):2179-2189
pubmed: 33504555
J Clin Oncol. 2005 Sep 20;23(27):6459-65
pubmed: 16116153
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35017153
Lancet Oncol. 2020 Jan;21(1):134-144
pubmed: 31780255
Front Immunol. 2023 Jul 24;14:1199145
pubmed: 37554322
J Clin Oncol. 2001 Nov 15;19(22):4189-94
pubmed: 11709561
J Immunother Cancer. 2020 May;8(1):
pubmed: 32414861
Annu Rev Med. 2015;66:49-63
pubmed: 25386934
J Clin Oncol. 2010 Nov 20;28(33):4969-75
pubmed: 20921469
Nat Rev Genet. 2019 Nov;20(11):657-674
pubmed: 31358977
Clin Cancer Res. 2009 Sep 15;15(18):5923-30
pubmed: 19737959
J Clin Invest. 2009 Jun;119(6):1524-36
pubmed: 19411762
Signal Transduct Target Ther. 2021 Feb 23;6(1):75
pubmed: 33619259
Nat Rev Dis Primers. 2016 Nov 10;2:16078
pubmed: 27830764
J Clin Oncol. 2012 Oct 1;30(28):3525-32
pubmed: 22927533
PLoS Med. 2018 Jan 29;15(1):e1002497
pubmed: 29377881
Nat Rev Cancer. 2003 Mar;3(3):203-16
pubmed: 12612655
J Clin Oncol. 2019 Apr 20;37(12):946-953
pubmed: 30811285
Cancer Res. 2001 May 15;61(10):4244-52
pubmed: 11358851
J Hematol Oncol. 2019 Jul 12;12(1):76
pubmed: 31300030
NPJ Breast Cancer. 2022 Sep 6;8(1):102
pubmed: 36068244
Sci Transl Med. 2017 Mar 15;9(381):
pubmed: 28298418
Cancers (Basel). 2020 Oct 10;12(10):
pubmed: 33050533
Front Immunol. 2020 Sep 02;11:1947
pubmed: 32983125
Cell Death Discov. 2022 Nov 28;8(1):468
pubmed: 36443299
Cancer Res. 2014 Jan 1;74(1):153-161
pubmed: 24247719
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
J Hematol Oncol. 2021 Oct 30;14(1):180
pubmed: 34717705
Trends Immunol. 2019 Apr;40(4):310-327
pubmed: 30890304
N Engl J Med. 2010 Sep 30;363(14):1324-34
pubmed: 20879881
Clin Cancer Res. 2016 Aug 1;22(15):3849-59
pubmed: 26957560
Int J Oncol. 1998 Jun;12(6):1299-306
pubmed: 9592190
Blood. 1998 Mar 1;91(5):1706-15
pubmed: 9473237
Sci Transl Med. 2010 Dec 22;2(63):63ra94
pubmed: 21178137
Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):8070-5
pubmed: 26080408
Int J Mol Sci. 2020 Nov 23;21(22):
pubmed: 33238631
Chem Rev. 2022 Mar 23;122(6):5977-6039
pubmed: 35107989
Nat Commun. 2021 Jan 21;12(1):511
pubmed: 33479234
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7
pubmed: 22451913
J Clin Oncol. 2012 Feb 1;30(4):426-32
pubmed: 22203761
J Exp Med. 2004 May 3;199(9):1213-21
pubmed: 15123743
MAbs. 2013 Sep-Oct;5(5):801-9
pubmed: 23924804
Cancers (Basel). 2020 Jul 25;12(8):
pubmed: 32722460
Clin Cancer Res. 2016 Mar 15;22(6):1364-70
pubmed: 26534966
J Clin Oncol. 1987 Sep;5(9):1430-40
pubmed: 3625258
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
Cancer Res. 1986 Jan;46(1):440-3
pubmed: 3940209
Eur J Cancer. 2021 Feb;144:123-150
pubmed: 33341446
Mol Immunol. 2005 Jul;42(11):1311-9
pubmed: 15950727
J Immunother Cancer. 2021 May;9(5):
pubmed: 34016720
Cancer. 1997 Jul 15;80(2):317-33
pubmed: 9217046